Contact
searchSearch
HMP Global
Login
Sally Lau, MD
Videos
Tarlatamab Plus PD-L1 Inhibitor as Potential First-Line Maintenance for Extensive-Stage Small Cell Lung Cancer
10/08/2024
Sally Lau, MD, discusses results from the phase 1b DeLLphi-303 study which demonstrated that tarlatamab plus a PD-L1 inhibitor exhibited efficacy as a first-line maintenance therapy for patients with extensive-stage small cell lung cancer.
Sally Lau, MD, discusses results from the phase 1b DeLLphi-303 study which demonstrated that tarlatamab plus a PD-L1 inhibitor exhibited efficacy as a first-line maintenance therapy for patients with extensive-stage small cell lung cancer.
Sally Lau, MD, discusses results...
10/08/2024
Oncology
Conference Coverage
Durvalumab With Chemotherapy And Novel Agents for Early-Stage, Resectable Non-Small Cell Lung Cancer
09/11/2024
The NeoCOAST-2 trial found durvalumab, single-agent platinum chemotherapy, and datopotamab deruxtecan to yield the highest pCR rate among patients with early-stage resectable non-small cell lung cancer, when compared to other combinations.
The NeoCOAST-2 trial found durvalumab, single-agent platinum chemotherapy, and datopotamab deruxtecan to yield the highest pCR rate among patients with early-stage resectable non-small cell lung cancer, when compared to other combinations.
The NeoCOAST-2 trial found...
09/11/2024
Oncology
Conference Coverage
Ivonescimab As New First-Line Treatment Option for Patients with PD-L1–Positive, Advanced Non-Small Cell Lung Cancer
09/09/2024
Ivonescimab showed a clinically meaningful and statistically significant improvement to progression-free survival for patients with PD-L1–positive, advanced non-small cell lung cancer, when compared with pembrolizumab.
Ivonescimab showed a clinically meaningful and statistically significant improvement to progression-free survival for patients with PD-L1–positive, advanced non-small cell lung cancer, when compared with pembrolizumab.
Ivonescimab showed a clinically...
09/09/2024
Oncology
Conference Coverage
Addition of Anlotinb to Durvalumab Maintenance Improved Survival Results Among Patients With Extensive-Stage Small Cell Lung Cancer
09/09/2024
Results from the phase 2 DURABLE trial demonstrated that durvalumab plus anlotinib in the maintenance setting improved survival results compared to durvalumab alone among patients with extensive-stage small cell lung cancer.
Results from the phase 2 DURABLE trial demonstrated that durvalumab plus anlotinib in the maintenance setting improved survival results compared to durvalumab alone among patients with extensive-stage small cell lung cancer.
Results from the phase 2 DURABLE...
09/09/2024
Oncology
Conference Coverage
Sacituzumab Govetican Shows Promise for Second-Line Extensive-Stage Small Cell Lung Cancer
09/05/2024
According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...
According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...
According to updated results...
09/05/2024
Oncology
Alexander Spira, MD, PhD
Videos
Antitumor Activity of Amivantamab Among Patients With METex14 Non-Small Cell Lung Cancer
09/13/2023
Alexander Spira, MD, PhD, discusses the efficacy of amivantamab among patients with METex14 NSCLC enrolled in the CHRYSALIS study, as presented at the 2023 World Conference on Lung Cancer.
Alexander Spira, MD, PhD, discusses the efficacy of amivantamab among patients with METex14 NSCLC enrolled in the CHRYSALIS study, as presented at the 2023 World Conference on Lung Cancer.
Alexander Spira, MD, PhD,...
09/13/2023
Oncology
Alexander Spira, MD, PhD
Videos
Amivantamab, Lazertinib, and Chemotherapy Quadruplet Therapy Demonstrated Durable Response Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer
09/13/2023
Alexander Spira, MD, PhD, discusses updated results from the CHRYSALIS-2 study, in which amivantamab and lazertinib plus chemotherapy demonstrated durable and meaningful responses among patients with EGFR-mutated NSCLC, as presented at the...
Alexander Spira, MD, PhD, discusses updated results from the CHRYSALIS-2 study, in which amivantamab and lazertinib plus chemotherapy demonstrated durable and meaningful responses among patients with EGFR-mutated NSCLC, as presented at the...
Alexander Spira, MD, PhD,...
09/13/2023
Oncology
Tetsuya Mitsudomi, MD, PhD
Videos
Addition of Perioperative Durvalumab to Neoadjuvant Chemotherapy Did Not Adversely Affect Surgical Outcomes Among Patients With Resectable Non-Small Cell Lung Cancer
09/12/2023
At the 2023 World Conference on Lung Cancer, Tetsuya Mitsudomi, MD, PhD, presented results which demonstrated the addition of perioperative durvalumab to neoadjuvant chemotherapy did not adversely affect surgical outcomes among patients with...
At the 2023 World Conference on Lung Cancer, Tetsuya Mitsudomi, MD, PhD, presented results which demonstrated the addition of perioperative durvalumab to neoadjuvant chemotherapy did not adversely affect surgical outcomes among patients with...
At the 2023 World Conference on...
09/12/2023
Oncology
Conference Coverage
Toripalimab With First-Line Chemotherapy Yields Superiority in Advanced NSCLC
09/13/2021
Data from the CHOICE-01 phase 3 trial confirm that toripalimab in combination with first-line chemotherapy showed superior PFS, ORR, and DOR, with a manageable safety profile in patients with advanced NSCLC.
Data from the CHOICE-01 phase 3 trial confirm that toripalimab in combination with first-line chemotherapy showed superior PFS, ORR, and DOR, with a manageable safety profile in patients with advanced NSCLC.
Data from the CHOICE-01 phase 3...
09/13/2021
Oncology
Conference Coverage
Camrelizumab Plus Apatinib Yields Promising Activity in Advanced NSCLC
09/13/2021
Results of a phase 2 trial reveal promising clinical activity for camrelizumab plus apatinib as a combination treatment in the frontline setting for patients with non-squamous NSCLC at the virtual 2021 World Conference on Lung Cancer.
Results of a phase 2 trial reveal promising clinical activity for camrelizumab plus apatinib as a combination treatment in the frontline setting for patients with non-squamous NSCLC at the virtual 2021 World Conference on Lung Cancer.
Results of a phase 2 trial...
09/13/2021
Oncology
Dr Spira
Videos
Dr Spira Highlights Amivantamab as Promising Treatment in METex14 Mutated NSCLC
09/10/2021
Alexander Spira, MD, PhD, FACP, discusses new evidence supporting the use of the amivantamab in the treatment of patients with NSCLC with MET exon 14 skipping (METex14) mutations, to be presented at the IASLC 2021 World Conference on Lung...
Alexander Spira, MD, PhD, FACP, discusses new evidence supporting the use of the amivantamab in the treatment of patients with NSCLC with MET exon 14 skipping (METex14) mutations, to be presented at the IASLC 2021 World Conference on Lung...
Alexander Spira, MD, PhD, FACP,...
09/10/2021
Oncology
Conference Coverage
Greater Immune Protection Against SARS-CoV-2 Needed in Lung Cancer Therapy
09/10/2021
An ongoing cohort study found that although most lung cancer patients have displayed promising antibody responses to SARS-CoV-2 vaccinations, a subgroup exhibited significantly lower antibody/neutralizing levels, indicating further studies...
An ongoing cohort study found that although most lung cancer patients have displayed promising antibody responses to SARS-CoV-2 vaccinations, a subgroup exhibited significantly lower antibody/neutralizing levels, indicating further studies...
An ongoing cohort study found...
09/10/2021
Oncology
Conference Coverage
Real-World Data Shows Lurbinectedin Beneficial for Pretreated SCLC and Mesothelioma
09/10/2021
Lurbinectedin offers clinical benefit for heavily pretreated patients with small cell lung cancer and mesothelioma, according to real-world data presented at the 2021 IASLC World Conference on Lung Cancer.
Lurbinectedin offers clinical benefit for heavily pretreated patients with small cell lung cancer and mesothelioma, according to real-world data presented at the 2021 IASLC World Conference on Lung Cancer.
Lurbinectedin offers clinical...
09/10/2021
Oncology

Experts from across the globe participate, discover, and share groundbreaking research in the IASLC 2021 World Conference on Lung Cancer of the International Association for the Study of lung Cancer.

Tracks

Lung Cancer

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use